OBJECTIVE: MicroRNA-221 (miR-221), which is located on chromosome X, is an oncogenic microRNA that is involved in several human malignancies. This study aimed to characterize the role of miR-221 in the initiation and malignant progression of gastric cancer. METHODS: The level of miR-221 expression in 92 pairs of primary gastric tumour tissue and adjacent nontumour tissue was quantified by real-time reverse transcriptionpolymerase chain reaction. The relationship between the miR-221 level and clinicopathological features was explored. RESULTS: MiR-221 was upregulated in 88% (81/92) of gastric cancer tissue samples compared with their paired adjacent nontumour tissue samples. High expression of miR-221 showed a significant correlation with advanced tumour-node-metastasis stage, local invasion and lymphatic metastasis. Univariate and multivariate Cox proportional hazard regression analyses revealed that miR-221 overexpression was an unfavourable prognostic factor for overall survival in patients with gastric cancer. CONCLUSIONS: These findings suggest that miR-221 is a novel prognostic indicator in gastric cancer and may be a potential target for diagnosis and gene therapy.
Introduction
Despite its declining incidence in Western countries over the past 50 years, gastric cancer remains the second most frequently diagnosed cancer worldwide, with approximately 870 000 new cases and 650 000 deaths per year. 1 Approximately 85% of patients with gastric cancer are diagnosed at an advanced clinical stage 2 and the 5-year survival rate is poor, despite the development of multimodal treatment strategies involving surgery, chemotherapy and radiation. 3 Gastric cancer is the leading cause of cancer-related death in China, with an average mortality rate of 26% for males and 15% for females. 4 Although previous research has identified a variety of molecules associated with the oncogenesis and development of gastric cancer, 5 6 This binding results in the degradation of the target mRNA or inhibition of translation, and occurs in plants and animals. 7 More than 700 miR sequences have been identified in the human genome and recorded in the miRBase version 13.0 database (available at: http://www.mirbase.org/). This number is predicted to double, as many miRs are awaiting experimental validation. MiRs have important regulatory functions in basic biological processes including development, cellular differentiation, proliferation and apoptosis. 8 In addition, about 50% of miRs are located in cancer-associated genomic regions or at fragile sites, 9 and are frequently misexpressed or mutated in cancer patients. 10 MiRs have been shown to play important roles in the multistep process of carcinogenesis, functioning either as oncogenes or tumour suppressors, depending on whether they specifically target tumour suppressor genes or oncogenes. 11 Oncogenic miRs are usually overexpressed in tumours, while tumour-suppressive miRs are underexpressed. 11 Overexpression of miR-221 has been reported in many malignancies including gastric cancer, 12 urinary bladder cancer, 13 colorectal cancer, 14 breast cancer, 15 pancreatic cancer, 16 papillary thyroid carcinoma, 17 hepatocellular carcinoma, 18 glioblastoma, 19 cutaneous melanoma 20 and lymphoma. 21 Investigations have revealed a close association between the level of miR-221 expression and clinicopathological tumour features including tumour-node-metastasis (TNM) stage, local invasion, metastasis, prognosis, radiosensitivity and anticancer drug resistance, 22, 23 but it is unknown whether miR-221 contributes to the malignant progression and metastasis of gastric cancer.
This study compared miR-221 expression levels in samples of gastric tumour tissue and adjacent nontumour tissue, and investigated the clinicopathological and prognostic value of miR-221 in gastric cancer.
Patients and methods

STUDY POPULATION
Paired samples of primary gastric tumour tissue and adjacent nontumour tissue (> 3 cm from the tumour tissue) were surgically obtained from consecutive patients with histologically proven gastric cancer, who underwent curative resections between September 2005 and January 2007 at the Department of General Surgery, Jinling Hospital, Nanjing, China. Patients with a previous or secondary malignancy, uncontrolled or serious infection, and/or those who had undergone radiation therapy, chemotherapy or immunotherapy, were excluded from the study. Tissues were flash frozen and stored at -80°C in liquid nitrogen after surgery. Tumours were staged using the TNM staging system of the International Union Against Cancer. 24 Histological grade was determined according to World Health Organization criteria. 25 Local invasion was assessed using T staging, 24 and lymphatic status was recorded as positive or negative. The Medical Ethics Committee of Jinling Hospital approved the study and all patients provided written informed consent.
RNA EXTRACTION AND QUANTITATIVE REAL-TIME RT-PCR
Total RNA from 20 -50 mg of gastric tumour samples and their corresponding adjacent K Liu, G Li, C Fan et al. MicroRNA-221 in human gastric cancer nontumour tissue samples was isolated using TRIzol ® reagent (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's instructions. RNA quality and quantity were assessed using a Bioanalyzer 2100 system (Agilent Technologies, Santa Clara, CA, USA). The miR-221 and RNA U6 (as an internal control) specific complementary DNA were synthesized from total RNA using gene-specific primers and the TaqMan ® miRNA assay system (Applied Biosystems, Foster City, CA, USA). Reverse transcription (RT) primer sequences (Invitrogen) were 5′-GTCGTATCCAGTGCAGGGTCCGAGGTATTC GCACTGGATACGACGAAACCCA-3′
(for miR-221) and 5′-CGTTCACGAATTTGCGT GTCAT-3′ (for RNA U6). The RT reaction mixture contained 10 ng total RNA, 50 nmol/l RT primer, 1 × RT buffer, 0.25 mmol/l each deoxynucleotide triphosphate, 3.33 U/µl MultiScribe ® reverse transcriptase and 0.25 U/µl RNase inhibitor in a total volume of 7.5 µl (Applied Biosystems). Reactions were incubated in a 96-well plate for 30 min at 16°C, followed by 30 min at 42°C and 5 min at 85°C, and then held at 4°C.
Real-time polymerase chain reaction (PCR) was performed using the 7500 realtime PCR system (Applied Biosystems). Reactions were carried out in 96-well plates in a total volume of 10 µl (0.67 µl RT products, 1 × TaqMan ® Universal PCR master mix, and 1 µl TaqMan ® miRNA assay primer and probe mix). The cycling programme involved preliminary denaturation at 95°C for 10 min, followed by 45 cycles of denaturation at 95°C for 15 s, annealing at 55°C for 30 s and elongation at 70°C for 30 s, followed by a final elongation step at 60°C for 10 min. All samples were processed in triplicate. The threshold cycle (C T ) was defined as the cycle number at which the fluorescence passed the fixed threshold, and the relative amount of miR-221 to U6 was calculated using the equation 2 -∆C T , where ∆C T = (C T miR-221 − C T U6 ). 26
PATIENT FOLLOW-UP
Follow-up was performed at 3-month intervals for 1 year, then at 6-month intervals for 3 years and annually for the remaining duration of the study. The followup examinations consisted of a physical examination, complete blood count, liver function tests, measurement of serum tumour markers, and abdominal and pelvic computed tomography scans. Patients underwent chest X-ray examination and gastroscopy every 6 months, regardless of their follow-up schedule. Survival time was calculated from the date of the resection to the date of death or last follow-up.
STATISTICAL ANALYSES
Data were expressed as mean ± SD. Differences in miR-221 expression levels between groups were compared using Student's t-test. Overall survival was calculated using the Kaplan-Meier method, and the log-rank test was performed to compare the differences between survival curves. The joint effect of covariables was examined using the Cox proportional hazards regression model. Statistical analysis was performed with SPSS ® version 17.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . All tests were two-tailed and a P-value < 0.05 was considered statistically significant.
Results
Paired samples of primary gastric tumour tissues and adjacent nontumour tissues were surgically obtained from 92 patients (50 males, 42 females; mean ± SD age 59. The correlation between miR-221 expression levels and clinicopathological characteristics of patients is summarized in Table 1 . High miR-221 expression was significantly correlated with advanced clinical stage (P = 0.021), local invasion (P = 0.008) and lymphatic metastasis (P = 0.039). No correlation was observed between miR-221 expression level and age, gender or degree of tumour cell differentiation.
At the time of these analyses (June 2011), 14 of the 92 patients (15%) remained alive. The median duration of follow-up was 40 months (range 10 -68 months). Follow-up examinations revealed that 53 patients had metastases (i.e. systemic recurrence) at the first sign of relapse whereas, in 17 patients, relapse was determined to be due to locoregional recurrence. Three patients had both locoregional recurrence and metastatic disease at the first sign of relapse.
Using the mean level of miR-221 (2.59 ∆C T ), the patients were divided into two groups: miR-221 low expressers (n = 44) and miR-221 high expressers (n = 48). The difference in survival between the two groups, stratified according to the level of miR-221 expression, is shown in Fig. 1 . The 5-year survival rates in miR-221 low and high expressers were 32% and 20%, respectively, with corresponding median survival times of 43 and 34 months, respectively (P = 0.018, both comparisons). Table 2 presents the results of the univariate and multivariate Cox 
Discussion
The discovery of miRs has substantially changed the understanding of gene regulation; research findings have underlined the importance of miRs in cancer molecular biology. In particular, miR-221 has been demonstrated to be an important oncogenic miR in many cancers, 12 -21 but the associations between miR-221 expression levels, clinicopathological characteristics and survival in patients with gastric cancer remain K Liu, G Li, C Fan et al.
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unknown. Although gene expression profiling has revealed several molecular changes associated with gastric cancer, 27, 28 biological markers that precisely predict progression and prognosis are not yet available. In the present study, miR-221 was significantly overexpressed in gastric tumour samples compared with adjacent nontumour tissue samples, and increased expression of miR-221 was associated with advanced clinical stage, local invasion, lymphatic metastasis and poor survival. These findings are in agreement with previous studies. Gramantieri et al. 22 revealed a trend towards a more aggressive phenotype and a reduced time to recurrence after surgery in hepatocellular carcinoma patients with high miR-221 expression levels. In addition, up-regulated miR-221 expression was positively correlated with advanced TNM stage and deep local infiltration in colorectal carcinoma, and anti-miR-221 markedly inhibited cell proliferation and induced apoptosis. 29 The human gastric cancer cell line, SGC7901, displayed significantly increased invasive ability when transfected with active miR-221/222 precursor, and SGC7901 cells transfected with anti-miR-221/222 had markedly decreased invasion potential. 30 Taken together, these findings suggest that miR-221 might play an important role in tumour initiation, and in the development and progression of malignancy.
Studies have begun to reveal the underlying molecular mechanisms that link miR-221 overexpression to cancer, and several functional targets have been identified. It is well known that miR-221 promotes cell-cycle progression in cancer cells (from G 0 /G 1 to S phase) and facilitates cell proliferation via down-regulation of p27 Kip1 and p57 Kip2 , cell-cycle inhibitors and 31 -33 It has also been confirmed that c-Kit, a common oncogenic protein, is downstream of miR-221 in gastrointestinal stromal tumours, 34 prostate cancer, 35 papillary thyroid carcinoma 17 and leukaemic cells. 36 Enforced miR-221 expression induced the down-regulation of B-cell lymphoma 2 modifying factor in hepatocellular carcinoma cell lines, which may be important for sensing intracellular damage and triggering apoptosis. 22 A similar phenotype has been observed in anti-miR-221/222 transfected gastric cancer cells, and in cells transfected with plasmid complementary DNA-phosphatase and tensin homologue (PTEN), including prolonged G 0 /G 1 phase transition, enhanced apoptosis and reduced cell invasive capacity. 30 This suggests an important role for PTEN as a mediator of the oncogenic effects of miR-221/222. A typical miR may have more than 100 targets 37 and a single mRNA may be regulated by a number of miRs; 38 therefore the mechanisms of miR-221-mediated tumorigenesis and development are not well understood. Determining the molecular characteristics of miR-221 is an important aspect of future investigations.
In conclusion, this study confirmed the overexpression of miR-221 in gastric tumour tissue samples compared with adjacent nontumour tissue samples, and demonstrated an association between the up-regulation of miR-221 and tumour progression and poor prognosis in patients with gastric cancer. These results suggest that miR-221 is a novel prognostic indicator in patients with gastric cancer and that it might be both a potential diagnostic biomarker and a molecular target for gene therapy.
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